Eisenmenger’s syndrome diagnostic study of choice

Jump to navigation Jump to search

Eisenmenger’s syndrome Microchapters


Patient Information


Historical Perspective




Differentiating Eisenmenger’s syndrome from other Diseases

Epidemiology and Demographics

Risk Factors


Natural History, Complications and Prognosis


Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings



Echocardiography and Ultrasound

CT scan


Other Imaging Findings

Other Diagnostic Studies

Eisenmenger’s syndrome ACC/AHA Guidelines for Evaluation of Patients


Medical Therapy


Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

ACC/AHA Guidelines for Reproduction

Eisenmenger’s syndrome diagnostic study of choice On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides


American Roentgen Ray Society Images of Eisenmenger’s syndrome diagnostic study of choice

All Images
Echo & Ultrasound
CT Images

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Eisenmenger’s syndrome diagnostic study of choice

CDC on Eisenmenger’s syndrome diagnostic study of choice

Eisenmenger’s syndrome diagnostic study of choice in the news

Blogs on Eisenmenger’s syndrome diagnostic study of choice

Directions to Hospitals Treating Type page name here

Risk calculators and risk factors for Eisenmenger’s syndrome diagnostic study of choice

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-In-Chief: Abdelrahman Ibrahim Abushouk, MD[2], Priyamavada Singh, MBBS [3], Kristin Feeney, B.S. [4]


2018 ACC/AHA Guidelines for the Management of Adults With Congenital Heart Disease (DO NOT EDIT)[1]

Class I
"1. Care of adult patients with CHD-related PAH should be performed in centers that have shared expertise and training in both ACHD and PAH. (Level of Evidence: C)"
"2. The evaluation of all ACHD patients with suspected PAH should include noninvasive assessment of cardiovascular anatomy and potential shunting, as detailed below:"
"a. Pulse oximetry, with and without administration of supplemental oxygen, as appropriate. (Level of Evidence: C)"
"b. Chest x-ray. (Level of Evidence: C)"
"c. ECG. (Level of Evidence: C)"
"d. Diagnostic cardiovascular imaging via TTE, TEE, MRI, or CT as appropriate. (Level of Evidence: C)"
"e. Complete blood count and nuclear lung scintigraphy. (Level of Evidence: C)"
"3. If PAH is identified but its causes are not fully recognized, additional testing should include the following:"
"a. Pulmonary function tests with volumes and diffusion capacity (diffusing capacity of the lung for carbon monoxide). (Level of Evidence: C)"
"b. Pulmonary embolism-protocol CT with parenchymal lung windows. (Level of Evidence: C)"
"c. Additional testing as appropriate to rule out contributing causes of PAH. (Level of Evidence: C)"
"d. Cardiac catheterization at least once, with potential for vasodilator testing or anatomic intervention, at a center with expertise in catheterization, PAH, and management of CHD-PAH. (Level of Evidence: C)"
Class IIa
"1. It is reasonable to include a 6-minute walk test or similar nonmaximal cardiopulmonary exercise test as part of the functional assessment of patients with CHD-PAH. (Level of Evidence: C)"